Combination of metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials | |
Zheng W1; Zhang Q2; Cai DB3; Yang XH1; Ungvari GS4; Ng CH5; Wu RR6; Xiang YT7![]() | |
2018 | |
Source Publication | Pharmacopsychiatry
![]() |
ISSN | 0176-3679 |
Abstract | INTRODUCTION:Weight gain is a common antipsychotic (AP)-related adverse drug reaction (ADR) that can increase the risk of cardiovascular diseases and premature mortality. This meta-analysis examined the efficacy and tolerability of combining metformin and lifestyle intervention for AP-related weight gain in schizophrenia. METHODS:Randomized controlled trials (RCTs) with meta-analyzable data were searched and retrieved by 2 independent investigators. RevMan software (version 5.3) was used to synthesize data, and to calculate the standardized or weighted mean differences and risk ratio with their 95% confidence intervals. RESULTS:Six RCTs (n=732) were included and meta-analyzed. The metformin and lifestyle combination (MLC) group had significant reduction in weight and body mass index compared with the metformin group, lifestyle group, and placebo group. There was less frequent weight gain of≥7% in the MLC group over placebo. No other group differences in ADRs, total psychopathology, and all-cause discontinuation were found. In terms of study quality, 5 RCTs were open-labelled, 1 RCT had low risk allocation concealment, and 3 RCTs specifically described randomization methods. CONCLUSION:Combining metformin and lifestyle intervention shows significant effect in reducing AP-related weight gain. Higher quality and larger RCTs are needed to confirm these findings.Review registration: CRD42017059198. |
Keyword | Metformin Meta-analysis Schizophrenia Weight Gain Lifestyle |
DOI | http://dx.doi.org/10.1055/s-0044-101466 |
Indexed By | SCI |
Language | 英语 |
WOS Research Area | Pharmacology & Pharmacy ; Psychiatry |
WOS Subject | Pharmacology & Pharmacy ; Psychiatry |
WOS ID | WOS:000455477400003 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | Faculty of Health Sciences |
Affiliation | 1.The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China. 2.The National Clinical Research Center for Mental Disorders, China & Center of Depression, Beijing Institute for Brain Disorders & Mood Disorders Center, Beijing Anding Hospital, Capital Medical University, Beijing, China. 3.Clinics of Chinese Medicine, First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China. 4.The University of Notre Dame Australia / Graylands Hospital, Perth, Australia. 5.Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia. 6.Mental Health Institute of the Second Xiangya Hospital & National Technology Institute of Psychiatry & Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, China. 7.Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China. |
Recommended Citation GB/T 7714 | Zheng W,Zhang Q,Cai DB,et al. Combination of metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials[J]. Pharmacopsychiatry,2018. |
APA | Zheng W.,Zhang Q.,Cai DB.,Yang XH.,Ungvari GS.,...&Xiang YT.(2018).Combination of metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials.Pharmacopsychiatry. |
MLA | Zheng W,et al."Combination of metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials".Pharmacopsychiatry (2018). |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment